Encapsulating drug molecules into microspheres enables controlled and sustained release. As microspheres can provide a sustained therapeutic effect, dosing frequency can be reduced and therefore patient compliance is improved.
Potential Benefits of Microencapsulation Include:
- Protection of Instable API
- Targeted ReleaseProfiles
- Sustained Release (Days to Months)
- Alternative Delivery Routes
- Reduced Side Effects
More than 10 sustained release, long-acting drug products, including LUPRON DEPOT®, BYDUREON®, RISPERDAL® CONSTA®, VIVITROL®, SANDOSTATIN® LAR DEPOT, DECAPEPTYL® LP, PROFACT DEPOT, have already been in the market places for years. Most of these depot products are based on poly(lactide-co-glycolide) (PLGA) microspheres and are administered subcutaneously or intramuscularly. The dosing frequency of these products ranges from once a week to once every six months, but mostly monthly. They are used to treat various diseases including prostate cancer, endometriosis, schizophrenia, diabetes, acromegaly, alcohol and drug addiction.
Phosphorex partners with customers to help them develop their unique sustained release, depot products. We support all phases of development, from proof of concept to clinical trials. Our experience includes but is not limited to encapsulating small molecules, proteins, peptides, ligands, nucleic acids, antibodies and dyes. We work with both hydrophobic and hydrophilic drug molecules.